771 related articles for article (PubMed ID: 9108448)
1. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
2. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma.
Ding WQ; Cheng ZJ; McElhiney J; Kuntz SM; Miller LJ
Cancer Res; 2002 Sep; 62(18):5223-9. PubMed ID: 12234988
[TBL] [Abstract][Full Text] [Related]
3. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
Körner M; Hayes GM; Rehmann R; Zimmermann A; Friess H; Miller LJ; Reubi JC
Am J Pathol; 2005 Oct; 167(4):959-68. PubMed ID: 16192632
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
6. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
7. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and functional characterization of a human secretin receptor.
Chow BK
Biochem Biophys Res Commun; 1995 Jul; 212(1):204-11. PubMed ID: 7612008
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
10. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
11. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
13. Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
Li GH; Qian W; Song GQ; Hou XH
J Gastroenterol Hepatol; 2007 Aug; 22(8):1328-35. PubMed ID: 17559364
[TBL] [Abstract][Full Text] [Related]
14. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
15. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig.
Dupont C; Broyart JP; Broer Y; Chenut B; Laburthe M; Rosselin G
J Clin Invest; 1981 Mar; 67(3):742-52. PubMed ID: 6259209
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
[TBL] [Abstract][Full Text] [Related]
17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
18. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.
Sreedharan SP; Patel DR; Huang JX; Goetzl EJ
Biochem Biophys Res Commun; 1993 Jun; 193(2):546-53. PubMed ID: 8390245
[TBL] [Abstract][Full Text] [Related]
19. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.
Hodges RR; Zoukhri D; Sergheraert C; Zieske JD; Dartt DA
Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):610-9. PubMed ID: 9071214
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation.
Juarranz MG; Bodega G; Prieto JC; Guijarro LG
Prostate; 2001 Jun; 47(4):285-92. PubMed ID: 11398176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]